Loading ...


  ACUTE AND CHRONIC KIDNEY DISEASE: SGLT2 inhibitors & risk of diabetic ketoacidosis (Sep. 2020)   A cohort study from Canad...


ACUTE AND CHRONIC KIDNEY DISEASE: SGLT2 inhibitors & risk of diabetic ketoacidosis (Sep. 2020)


A cohort study from Canada & UK that conducting almost 350,000 ptns in addition to 500 diabetic ketoacidosis (DKA) events, SGLT2 inhibitors (dapagliflozin (Forxiga), canagliflozin, empagliflozin), in comparison with dipeptidyl peptidase 4 (DPP-4) inhibitors, were currently complicated by a higher risk of DKA (a reported incidence 2.03 vs 0.75 /1000 person-ys). SGLT2 inhibitors should NOT be used with type 1 DM or with type 2 DM that was accompanied with factors that enhance the DKA development (e.g., pancreatic malfunction, drug addiction or alcohol abuse).  


Dose of Dapagliflozin (Forxiga) in adults with Renal dysfunction:

I. eGFR > 45 mL/minute/1.73 m2: No dosage adjustment necessary.    😚


II. eGFR 30 - <45 mL/minute/1.73 m2:

DM type II:

Ø  Hyperglycemia: The US manufacturer does NOT recommend use; use in other countries is variable   (ADA 2020).

Ø  Ptns with heart failure and/or atherosclerotic CVS: No dosage adjustment necessary for ptns with HF. The manufacturer in US states there is insufficient data supporting a dose recommendation in ptns without HF.

Ø  Diabetic kidney disease (off-label use): Some experts use dapagliflozin off label at a dose of 5 mg once/day in ptns with heavy albuminuria (e.g., urinary albumin >300 mg/d). (Perkovic 2020; Neuen 2019; Wiviott 2019).

Ø  Heart failure with EF decline: No dose adjustment is required.


III. eGFR <30 mL/minute/1.73 m2:

DM, type II: for hyperglycemia control: contraindicated.   

Use in ptns with HF and/or ptns with or at risk for atherosclerotic CVS disease: The US manufacturer states there is insufficient data to support a dose recommendation.                                                                                                                              Use in ptn with diabetic kidney disease (off-label use): Dapagliflozin should NOT be started; in ptns previously established on dapagliflozin, some experts continue use off-label with dose of 5 mg once daily (Perkovic 2020).                                                     

 HF with low EF:  no sufficient data to support dose recommendation.                                                         

ESRD, HDX: contraindicated.  

Douros A, Lix LM, Fralick M, et al. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis: A Multicenter Cohort Study. Ann Intern Med 2020; 173:417.



Arabic window,5,Hemodialysis,24,My Publications,4,Peritoneal dialysis,14,Prevention of renal failure,63,Renal face,43,Renal Transplantation,57,TOP RECENT,38,
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS PREMIUM CONTENT IS LOCKED STEP 1: Share to a social network STEP 2: Click the link on your social network Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy Table of Content